Standard BioTools (LAB) Resumen de Acciones
Standard BioTools Inc., junto con sus filiales, desarrolla, fabrica y vende una gama de instrumentación, consumibles y servicios a científicos e investigadores biomédicos para desarrollar terapias en América, Europa, Oriente Medio, África y Asia-Pacífico. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
LAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Standard BioTools Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.84 |
| Máximo en las últimas 52 semanas | US$1.72 |
| Mínimo de 52 semanas | US$0.70 |
| Beta | 1.42 |
| Cambio en 1 mes | -0.79% |
| Variación en 3 meses | -8.88% |
| Cambio de 1 año | -32.12% |
| Variación en 3 años | -65.22% |
| Variación en 5 años | -85.66% |
| Variación desde la OPV | -94.00% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 18
LAB: Merger With Treeline And 2026 Guidance Will Support Upside
Analysts have kept their average price target for Standard BioTools unchanged at $1.35. This steadiness reflects updated assumptions that now include a slightly higher discount rate, a smaller projected revenue decline, a largely similar profit margin outlook, and a marginally higher future P/E multiple.
Actualización de narrativa • Jun 04
LAB: Completed Buyback And Stable Guidance Will Support Future Earnings Profile
Analysts have adjusted their price target on Standard BioTools to $1.55, reflecting updated assumptions that now include a modest positive revenue growth outlook of 13.79%, a slightly higher long term profit margin of 15.57%, a small reduction in the discount rate to 7.83%, and a relatively stable future P/E of about 60x. What's in the News Standard BioTools reaffirmed earnings guidance for fiscal year 2026, continuing to expect revenue in the range of $80 million to $85 million.Actualización de narrativa • May 20
LAB: Stable 2026 Guidance And Completed Buyback Will Support Upside
Analysts have raised their $1.35 price target on Standard BioTools, pointing to slightly softer assumed revenue declines, a modest improvement in profit margin forecasts and a lower projected future P/E multiple as key drivers of the update. What's in the News Standard BioTools reaffirmed earnings guidance for fiscal 2026, continuing to expect revenue in the range of $80 million to $85 million.Recent updates
Actualización de narrativa • Jun 18
LAB: Merger With Treeline And 2026 Guidance Will Support Upside
Analysts have kept their average price target for Standard BioTools unchanged at $1.35. This steadiness reflects updated assumptions that now include a slightly higher discount rate, a smaller projected revenue decline, a largely similar profit margin outlook, and a marginally higher future P/E multiple.Actualización de narrativa • Jun 04
LAB: Completed Buyback And Stable Guidance Will Support Future Earnings Profile
Analysts have adjusted their price target on Standard BioTools to $1.55, reflecting updated assumptions that now include a modest positive revenue growth outlook of 13.79%, a slightly higher long term profit margin of 15.57%, a small reduction in the discount rate to 7.83%, and a relatively stable future P/E of about 60x. What's in the News Standard BioTools reaffirmed earnings guidance for fiscal year 2026, continuing to expect revenue in the range of $80 million to $85 million.Actualización de narrativa • May 20
LAB: Stable 2026 Guidance And Completed Buyback Will Support Upside
Analysts have raised their $1.35 price target on Standard BioTools, pointing to slightly softer assumed revenue declines, a modest improvement in profit margin forecasts and a lower projected future P/E multiple as key drivers of the update. What's in the News Standard BioTools reaffirmed earnings guidance for fiscal 2026, continuing to expect revenue in the range of $80 million to $85 million.Actualización de narrativa • Apr 28
LAB: Completed Buyback And 2026 Revenue Outlook Will Support Upside
Analysts have trimmed their price targets on Standard BioTools by $0.00, keeping fair value steady at $1.35 as they factor in a slightly lower discount rate, softer revenue growth assumptions, a marginally reduced profit margin outlook, and a modestly higher future P/E estimate. What's in the News On April 20, 2026, Standard BioTools received a Nasdaq notice that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180 day compliance period that runs until October 19, 2026 (Nasdaq listing notice).Actualización de narrativa • Apr 14
LAB: Completed Buybacks And 2026 Outlook Will Support Future Upside
Analysts have nudged their price target on Standard BioTools slightly higher to $1.35, reflecting minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping their overall valuation framework broadly unchanged. What's in the News Completion of a share repurchase program, with 13,603,617 shares bought back for a total of $35.91 million under the buyback announced on March 1, 2024 (Key Developments).Actualización de narrativa • Mar 31
LAB: Share Buybacks And Steady Outlook Will Support Future Upside
Analysts now see fair value for Standard BioTools holding at $1.35 per share, with a slightly higher discount rate and P/E assumptions, and a less steep projected revenue contraction supporting a steady price target despite mixed tweaks to the model inputs. What's in the News Standard BioTools completed a share repurchase program covering 13,603,617 shares, equal to 7.63% of the company, for a total of $35.91 million under the buyback announced on March 1, 2024 (Key Developments).Actualización de narrativa • Mar 17
LAB: Stable Guidance And Margin Assumptions Will Support Future Earnings Profile
Analysts have maintained their $1.55 price target on Standard BioTools, citing only marginal adjustments to the discount rate, long-term revenue and margin assumptions, along with a slightly higher future P/E expectation. What's in the News Issued earnings guidance for fiscal 2026 with expected revenue in the range of $80 million to $85 million, with seasonality described as similar to prior years (company guidance).Actualización de narrativa • Mar 03
LAB: Improved Margin Outlook And Stable Guidance Will Support Future Earnings Profile
Analysts have kept their $1.55 price target for Standard BioTools unchanged, citing slightly higher assumed profit margins and a modestly lower forward P/E, along with an updated view that revenue contraction is now far less severe than previously modeled. What's in the News Issued fiscal 2026 revenue guidance in a range of $80 million to $85 million, with seasonality expected to be similar to prior years (company guidance).
Actualización de narrativa • Feb 16
LAB: Imaging Collaboration And 2025 Outlook Will Drive Upside Potential
Analysts have modestly lifted their price target for Standard BioTools to $1.75, pointing to slightly higher assumed profit margins and a marginally richer future P/E multiple, even as they factor in a small additional revenue decline. What's in the News Standard BioTools issued revenue guidance for the fourth quarter of 2025, with expected revenue of approximately $56 million and revenue from continuing operations of about $24 million (company guidance).Artículo de análisis • Feb 12
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27%
Standard BioTools Inc. ( NASDAQ:LAB ) shareholders won't be pleased to see that the share price has had a very rough...Actualización de narrativa • Feb 02
LAB: Imaging Collaboration And Steady Guidance Will Shape Future Earnings Profile
Analysts have kept their price target for Standard BioTools steady at US$1.55, citing only minor tweaks to inputs such as discount rate, profit margin assumptions and future P/E, which did not meaningfully alter their overall valuation view. What's in the News Standard BioTools issued revenue guidance for the fourth quarter of 2025, with expected revenue of approximately US$56 million and revenue from continuing operations of about US$24 million.Artículo de análisis • Jan 29
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Actualización de narrativa • Jan 19
LAB: Higher Discount Rate Will Likely Undermine Outlook Despite Guidance
Analysts have trimmed their price target on Standard BioTools from US$1.55 to US$1.35, citing updated assumptions that now reflect a smaller expected revenue decline, a slightly stronger profit margin profile, a lower future P/E estimate, and a higher discount rate. What's in the News Standard BioTools issued revenue guidance for the fourth quarter of 2025, with expected revenue of about US$56 million and revenue from continuing operations of about US$24 million.Actualización de narrativa • Jan 05
LAB: Imaging Collaboration And 2025 Outlook Will Support Upside Potential
Analysts have kept their price target for Standard BioTools unchanged at US$1.75, citing only minor tweaks to inputs such as discount rate, revenue contraction assumptions and future P/E, which they view as offsetting each other at this stage. What's in the News Standard BioTools and Molecular Instruments announced a collaboration to develop next-generation Imaging Mass Cytometry workflows that combine HCR Gold for RNA and protein imaging with the Hyperion Imaging System, aiming to support simultaneous analysis of RNA and protein targets in complex tissues (Key Developments).Seeking Alpha • Dec 28
Standard BioTools: Outlook Still Murky
Summary Standard BioTools is trading near cash value post-SomaScan sale, with Casdin Capital raising its stake to 25%. LAB will receive $350M upfront and up to $75M in earnouts from Illumina for SomaScan, leaving $550M in cash post-transaction. Management projects Adj. EBITDA breakeven in 2026 after divestiture and a 20% workforce reduction, but ongoing operations lack clear growth catalysts. An analysis around Standard BioTools follows in the paragraphs below. Read the full article on Seeking AlphaActualización de narrativa • Dec 18
LAB: Earnings Outlook And Collaboration Will Drive Strong Upside Potential
Analysts have trimmed their price target on Standard BioTools from 2.00 dollars to 1.75 dollars, reflecting slightly higher perceived risk and softer revenue growth expectations, even as projected profit margins and future valuation multiples improve modestly. What's in the News Standard BioTools and Molecular Instruments announced a strategic collaboration to develop next generation Imaging Mass Cytometry workflows that integrate HCR RNA and protein imaging with the Hyperion Imaging System to boost sensitivity and flexibility in spatial biology research (Key Developments).Artículo de análisis • Dec 05
Subdued Growth No Barrier To Standard BioTools Inc. (NASDAQ:LAB) With Shares Advancing 26%
Standard BioTools Inc. ( NASDAQ:LAB ) shares have had a really impressive month, gaining 26% after a shaky period...Actualización de narrativa • Dec 04
LAB: Imaging Collaboration And Steady Outlook Will Support Future Earnings Profile
Analysts have modestly adjusted their price target on Standard BioTools, trimming fair value to approximately 1.55 dollars per share as they factor in a slightly higher discount rate, marginally softer long term profit margin expectations, and a higher projected future earnings multiple. What's in the News Molecular Instruments and Standard BioTools entered a strategic collaboration to develop next generation Imaging Mass Cytometry workflows powered by HCR imaging technologies, including the HCR HiFi Encoder for protein imaging with any primary antibody (Key Developments).Actualización de narrativa • Nov 20
LAB: Earnings Outlook Will Benefit From Advanced Imaging Collaboration
Analysts have adjusted their price target for Standard BioTools downward from $1.78 to $1.55. They cited updated expectations around revenue growth and profit margins.Actualización de narrativa • Aug 23
SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities
The downward revision in Standard BioTools' analyst price target reflects declining net profit margin and a higher future P/E ratio, with the consensus fair value now lowered to $1.78. What's in the News Standard BioTools announced a delay in filing their next 10-Q with the SEC.Artículo de análisis • Jul 10
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Is Still On The Mark Following 26% Share Price Bounce
The Standard BioTools Inc. ( NASDAQ:LAB ) share price has done very well over the last month, posting an excellent gain...Artículo de análisis • Jul 05
We're Keeping An Eye On Standard BioTools' (NASDAQ:LAB) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • May 24
Standard BioTools Inc. (NASDAQ:LAB) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
The Standard BioTools Inc. ( NASDAQ:LAB ) share price has fared very poorly over the last month, falling by a...
Nueva narrativa • Mar 26
SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities
Strategic mergers and partnerships, along with cost synergies, aim to improve profitability and net margins significantly.Artículo de análisis • Mar 01
Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's been a mediocre week for Standard BioTools Inc. ( NASDAQ:LAB ) shareholders, with the stock dropping 18% to...Artículo de análisis • Feb 21
Market Cool On Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 28% Lower
Standard BioTools Inc. ( NASDAQ:LAB ) shareholders won't be pleased to see that the share price has had a very rough...Artículo de análisis • Feb 09
Is Standard BioTools (NASDAQ:LAB) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Dec 17
After Leaping 35% Standard BioTools Inc. (NASDAQ:LAB) Shares Are Not Flying Under The Radar
Standard BioTools Inc. ( NASDAQ:LAB ) shares have had a really impressive month, gaining 35% after a shaky period...Artículo de análisis • Oct 26
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Sep 14
Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher
Those holding Standard BioTools Inc. ( NASDAQ:LAB ) shares would be relieved that the share price has rebounded 33% in...Artículo de análisis • Aug 05
Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Standard BioTools Inc. ( NASDAQ:LAB ) delivered a dose of negativity to shareholders today, by...Artículo de análisis • Jul 26
Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%
Those holding Standard BioTools Inc. ( NASDAQ:LAB ) shares would be relieved that the share price has rebounded 42% in...Artículo de análisis • Apr 09
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Standard BioTools Inc. ( NASDAQ:LAB ), might not be a large cap stock, but it led the NASDAQGS gainers with a...Artículo de análisis • Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Standard BioTools fair value estimate is US$3.18 Current share...Rentabilidad de los accionistas
| LAB | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | -4.5% | 2.2% | 0.2% |
| 1Y | -32.1% | 23.6% | 19.6% |
Rentabilidad vs. Industria: Los resultados de LAB fueron inferiores a los de la industria US Life Sciences, que obtuvo un rendimiento del 23.6% el año pasado.
Rentabilidad vs. Mercado: LAB obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.6% el año pasado.
Volatilidad de los precios
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 12.7% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de LAB ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LAB(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1999 | 387 | Michael Egholm | www.standardbio.com |
Standard BioTools Inc., junto con sus filiales, desarrolla, fabrica y vende una gama de instrumentación, consumibles y servicios a científicos e investigadores biomédicos para desarrollar terapias en América, Europa, Oriente Medio, África y Asia-Pacífico. La empresa opera a través de los segmentos de proteómica y genómica. Sus segmentos de proteómica y genómica incluyen instrumentos, consumibles y ensayos para usos clínicos y de diagnóstico.
Resumen de fundamentos de Standard BioTools Inc.
| Estadísticas fundamentales de LAB | |
|---|---|
| Capitalización bursátil | US$327.09m |
| Beneficios(TTM) | -US$50.08m |
| Ingresos (TTM) | US$86.26m |
3.8x
Ratio precio-ventas (PS)-6.6x
Ratio precio-beneficio (PE)¿Está LAB sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LAB | |
|---|---|
| Ingresos | US$86.26m |
| Coste de los ingresos | US$40.31m |
| Beneficio bruto | US$45.95m |
| Otros gastos | US$96.03m |
| Beneficios | -US$50.08m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.13 |
| Margen bruto | 53.27% |
| Margen de beneficio neto | -58.06% |
| Ratio deuda/patrimonio | 0.05% |
¿Cómo se ha desempeñado LAB a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/15 02:23 |
| Precio de las acciones al final del día | 2026/07/15 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Standard BioTools Inc. está cubierta por 12 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |